Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2019 · 10-Q
Revenue$72.94M$72.94M+3.9% vs Q3 2018 Net Income-$6.11M-$6.11MN/M vs Q3 2018 EPS Diluted-$0.18-$0.18N/M vs Q3 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,069,000−85.5% Free Cash Flowderived$4,718,000−87.9% Margins · derivedGross margin35.9%
Operating margin-8.7%+7.2 pt vs Q3 2018
Net margin-8.4%+15.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 6, 2019 · 37 d after period end